May 20, 2025
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics’ investigational novel conditionally activated IL-2 pro-drug WTX-124
WATERTOWN, Mass., May 20, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)